NVCT NASDAQ
Nuvectis Pharma, Inc.
1W: +3.9%
1M: -27.1%
3M: +126.5%
YTD: +132.9%
1Y: +154.8%
3Y: +32.0%
$19.82
+0.28 (+1.43%)
Pre-Market: $18.94 (-0.88, -4.47%)
Weekly Expected Move ±19.9%
$12
$15
$19
$23
$27
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$1.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$526.0M
52W Range5.55-29.275
Volume195,509
Avg Volume283,491
Beta-0.25
Dividend—
Analyst Ratings
Company Info
CEORon Bentsur
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-04
Websitenuvectis.com
1 Bridge Plaza
Fort Lee, NJ 07024
US
Fort Lee, NJ 07024
US
201 614 3150
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Latest News
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Nuvectis Pharma (NASDAQ:NVCT) Trading 1.1% Higher – Here’s What Happened
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Catalyst Watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BENTSUR RON | P-Purchase | 12,500 | $20.00 | 2026-06-30 |
| Mosseri Marlio Charl | P-Purchase | 50,000 | $18.32 | 2026-06-30 |
| Hoberman Kenneth | A-Award | 35,000 | — | 2026-06-11 |
| Oliviero James F III | A-Award | 35,000 | — | 2026-06-11 |
| Sanchez Juan | A-Award | 35,000 | — | 2026-06-11 |